中国防痨杂志 ›› 2022, Vol. 44 ›› Issue (9): 973-977.doi: 10.19982/j.issn.1000-6621.20220122
收稿日期:
2022-04-12
出版日期:
2022-09-10
发布日期:
2022-09-05
通信作者:
陆宇
E-mail:luyu4876@hotmail.com
基金资助:
Received:
2022-04-12
Online:
2022-09-10
Published:
2022-09-05
Contact:
Lu Yu
E-mail:luyu4876@hotmail.com
Supported by:
摘要:
随着耐多药结核病(multidrug-resistant tuberculosis,MDR-TB)和广泛耐药结核病(extensively drug-resistant tuberculosis,XDR-TB)菌株的增多,结核分枝杆菌(Mycobacterium tuberculosis,MTB)的耐药性成为全球亟待解决的问题。贝达喹啉(bedaquiline,Bdq)作为近50年来首个明确用于MDR-TB治疗的新药,其耐药问题受到逐步关注。笔者对Bdq的耐药特征和耐药基因突变等研究进展进行综述,旨在更好指导临床用药,提高患者的治疗成功率,减少耐药的发生。
中图分类号:
姚蓉, 陆宇. 抗结核药物贝达喹啉的耐药情况及其耐药机制研究进展[J]. 中国防痨杂志, 2022, 44(9): 973-977. doi: 10.19982/j.issn.1000-6621.20220122
Yao Rong, Lu Yu. Research progress on the drug resistance and mechanism of the anti-tuberculosis drug bedaquiline[J]. Chinese Journal of Antituberculosis, 2022, 44(9): 973-977. doi: 10.19982/j.issn.1000-6621.20220122
[1] | World Health Organization. Global tuberculosis report 2021. Geneva: World Health 0rganization,2021. |
[2] |
Koul A, Vranckx L, Dhar N, et al. Delayed bactericidal response of Mycobacterium tuberculosis to bedaquiline involves remodelling of bacterial metabolism. Nat Commun, 2014, 5:3369. doi: 10.1038/ncomms4369.
doi: 10.1038/ncomms4369 URL |
[3] |
中华医学会结核病学分会. 抗结核新药贝达喹啉临床应用专家共识(2020年更新版). 中华结核和呼吸杂志, 2021, 44(2):81-87. doi: 10.3760/cma.j.cn112147-20200714-00805.
doi: 10.3760/cma.j.cn112147-20200714-00805 |
[4] |
王晓英, 罗明, 张汇征, 等. 结核分枝杆菌贝达喹啉和氯法齐明耐药及其交叉耐药机制研究进展. 中国人兽共患病学报, 2022, 38(2):165-169. doi: 10.3969/j.issn.1002-2694.2021.00.031.
doi: 10.3969/j.issn.1002-2694.2021.00.031 |
[5] | World Health Organization. The Use of Bedaquiline in the Treatment of Multidrug-Resistant Tuberculosis: Interim Policy Guidance. Geneva: World Health Organization, 2013. |
[6] |
Diacon AH, Pym A, Grobusch MP, et al. Multidrug-resistant tuberculosis and culture conversion with bedaquiline. N Engl J Med, 2014, 371(8):723-732. doi: 10.1056/NEJMoa1313865.
doi: 10.1056/NEJMoa1313865 URL |
[7] |
Pontali E, Sotgiu G, D’Ambrosio L, et al. Bedaquiline and multidrug-resistant tuberculosis: a systematic and critical analysis of the evidence. Eur Respir J, 2016, 47(2):394-402. doi: 10.1183/13993003.01891-2015.
doi: 10.1183/13993003.01891-2015 URL |
[8] |
Mirzayev F, Viney K, Linh NN, et al. World Health Organization recommendations on the treatment of drug-resistant tuberculosis, 2020 update. Eur Respir J, 2021, 57(6):2003300. doi: 10.1183/13993003.03300-2020.
doi: 10.1183/13993003.03300-2020 |
[9] |
Singh P, Kumari R, Lal R. Bedaquiline: Fallible Hope Against Drug Resistant Tuberculosis. Indian J Microbiol, 2017, 57(4):371-377. doi: 10.1007/s12088-017-0674-0.
doi: 10.1007/s12088-017-0674-0 URL |
[10] |
Wu SH, Chan HH, Hsiao HC, et al. Primary Bedaquiline Resistance Among Cases of Drug-Resistant Tuberculosis in Taiwan. Front Microbiol, 2021, 12:754249. doi: 10.3389/fmicb.2021.754249.
doi: 10.3389/fmicb.2021.754249 URL |
[11] |
He W, Liu C, Liu D, et al. Prevalence of Mycobacterium tuberculosis resistant to bedaquiline and delamanid in China. J Glob Antimicrob Resist, 2021, 26:241-248. doi: 10.1016/j.jgar.2021.06.007.
doi: 10.1016/j.jgar.2021.06.007 URL |
[12] |
Huang H, Ding N, Yang T, et al. Cross-sectional Whole-genome Sequencing and Epidemiological Study of Multidrug-resistant Mycobacterium tuberculosis in China. Clin Infect Dis, 2019, 69(3):405-413. doi: 10.1093/cid/ciy883.
doi: 10.1093/cid/ciy883 URL |
[13] |
Liu Y, Gao M, Du J, et al. Reduced Susceptibility of Mycobacterium tuberculosis to Bedaquiline During Antituberculosis Treatment and Its Correlation With Clinical Outcomes in China. Clin Infect Dis, 2021, 73(9):e3391-e3397. doi: 10.1093/cid/ciaa1002.
doi: 10.1093/cid/ciaa1002 |
[14] |
Ismail NA, Omar SV, Joseph L, et al. Defining Bedaquiline Susceptibility, Resistance, Cross-Resistance and Associated Genetic Determinants: A Retrospective Cohort Study. EBioMedicine, 2018, 28:136-142. doi: 10.1016/j.ebiom.2018.01.005.
doi: S2352-3964(18)30005-7 pmid: 29337135 |
[15] |
Veziris N, Bernard C, Guglielmetti L, et al. Rapid emergence of Mycobacterium tuberculosis bedaquiline resistance: lessons to avoid repeating past errors. Eur Respir J, 2017, 49(3):1601719. doi: 10.1183/13993003.01719-2016.
doi: 10.1183/13993003.01719-2016 |
[16] |
Peretokina IV, Krylova LY, Antonova OV, et al. Reduced susceptibility and resistance to bedaquiline in clinical M.tuberculosis isolates. J Infect, 2020, 80(5):527-535. doi: 10.1016/j.jinf.2020.01.007.
doi: S0163-4453(20)30031-1 pmid: 31981638 |
[17] |
Kaniga K, Hasan R, Jou R, et al. Bedaquiline Drug Resistance Emergence Assessment in Multidrug-Resistant Tuberculosis (MDR-TB): a 5-Year Prospective In Vitro Surveillance Study of Bedaquiline and Other Second-Line Drug Susceptibility Testing in MDR-TB Isolates. J Clin Microbiol, 2022, 60(1):e291920. doi: 10.1128/JCM.02919-20.
doi: 10.1128/JCM.02919-20 |
[18] |
Mallick JS, Nair P, Abbew ET, et al. Acquired bedaquiline resistance during the treatment of drug-resistant tuberculosis: a systematic review. JAC Antimicrob Resist, 2022, 4(2):dlac029. doi: 10.1093/jacamr/dlac029.
doi: 10.1093/jacamr/dlac029 URL |
[19] |
Kunkel A, Cobelens FG, Cohen T. Tradeoffs in Introduction Policies for the Anti-Tuberculosis Drug Bedaquiline: A Model-Based Analysis. PLoS Med, 2016, 13(10):e1002142. doi: 10.1371/journal.pmed.1002142.
doi: 10.1371/journal.pmed.1002142 URL |
[20] |
Nimmo C, Millard J, van Dorp L, et al. Population-level emergence of bedaquiline and clofazimine resistance-associated variants among patients with drug-resistant tuberculosis in southern Africa: a phenotypic and phylogenetic analysis. Lancet Microbe, 2020, 1(4):e165-e174. doi: 10.1016/S2666-5247(20)30031-8.
doi: 10.1016/S2666-5247(20)30031-8 |
[21] |
Ghodousi A, Rizvi AH, Baloch AQ, et al. Acquisition of Cross-Resistance to Bedaquiline and Clofazimine following Treatment for Tuberculosis in Pakistan. Antimicrob Agents Chemother, 2019, 63(9):e00915-19. doi: 10.1128/AAC.00915-19.
doi: 10.1128/AAC.00915-19 |
[22] |
Mokrousov I, Akhmedova G, Molchanov V, et al. Frequent acquisition of bedaquiline resistance by epidemic extensively drug-resistant Mycobacterium tuberculosis strains in Russia during long-term treatment. Clin Microbiol Infect, 2021, 27(3):478-480. doi: 10.1016/j.cmi.2020.08.030.
doi: 10.1016/j.cmi.2020.08.030 URL |
[23] |
Kendall EA, Fofana MO, Dowdy DW. Burden of transmitted multidrug resistance in epidemics of tuberculosis: a transmission modelling analysis. Lancet Respir Med, 2015, 3(12):963-972. doi: 10.1016/S2213-2600(15)00458-0.
doi: 10.1016/S2213-2600(15)00458-0 pmid: 26597127 |
[24] |
Hartkoorn RC, Uplekar S, Cole ST. Cross-resistance between clofazimine and bedaquiline through upregulation of MmpL5 in Mycobacterium tuberculosis. Antimicrob Agents Chemother, 2014, 58(5):2979-2981. doi: 10.1128/AAC.00037-14.
doi: 10.1128/AAC.00037-14 pmid: 24590481 |
[25] |
Kadura S, King N, Nakhoul M, et al. Systematic review of mutations associated with resistance to the new and repurposed Mycobacterium tuberculosis drugs bedaquiline, clofazimine, linezolid, delamanid and pretomanid. J Antimicrob Chemother, 2020, 75(8):2031-2043. doi: 10.1093/jac/dkaa136.
doi: 10.1093/jac/dkaa136 pmid: 32361756 |
[26] |
Zimenkov DV, Nosova EY, Kulagina EV, et al. Examination of bedaquiline- and linezolid-resistant Mycobacterium tuberculosis isolates from the Moscow region. J Antimicrob Chemother, 2017, 72(7):1901-1906. doi: 10.1093/jac/dkx094.
doi: 10.1093/jac/dkx094 pmid: 28387862 |
[27] |
Pang Y, Zong Z, Huo F, et al. In Vitro Drug Susceptibility of Bedaquiline, Delamanid, Linezolid, Clofazimine, Moxifloxacin, and Gatifloxacin against Extensively Drug-Resistant Tuberculosis in Beijing, China. Antimicrob Agents Chemother, 2017, 61(10):e00900-17. doi: 10.1128/AAC.00900-17.
doi: 10.1128/AAC.00900-17 |
[28] |
Ghodousi A, Hussain RA, Khanzada FM, et al. In vivo microevolution of Mycobacterium tuberculosis and transient emergence of atpE_Ala63Pro mutation during treatment in a pre-XDR TB patient. Eur Respir J, 2022, 59(3):2102102. doi: 10.1183/13993003.02102-2021.
doi: 10.1183/13993003.02102-2021 |
[29] |
Gomez-Gonzalez PJ, Perdigao J, Gomes P, et al. Genetic diversity of candidate loci linked to Mycobacterium tuberculosis resistance to bedaquiline, delamanid and pretomanid. Sci Rep, 2021, 11(1):19431. doi: 10.1038/s41598-021-98862-4.
doi: 10.1038/s41598-021-98862-4 URL |
[30] |
Omar SV, Ismail F, Ndjeka N, et al. Bedaquiline-Resistant Tuberculosis Associated with Rv0678 Mutations. N Engl J Med, 2022, 386(1):93-94. doi: 10.1056/NEJMc2103049.
doi: 10.1056/NEJMc2103049 URL |
[31] |
Miotto P, Zhang Y, Cirillo DM, et al. Drug resistance mechanisms and drug susceptibility testing for tuberculosis. Respirology, 2018, 23(12):1098-1113. doi: 10.1111/resp.13393.
doi: 10.1111/resp.13393 pmid: 30189463 |
[32] |
Kaniga K, Aono A, Borroni E, et al. Validation of Bedaquiline Phenotypic Drug Susceptibility Testing Methods and Breakpoints: a Multilaboratory, Multicountry Study. J Clin Microbiol, 2020, 58(4):e01677-19. doi: 10.1128/JCM.01677-19.
doi: 10.1128/JCM.01677-19 |
[33] |
Gashaw F, Erko B, Mekonnen Y, et al. Phenotypic and genotypic drug sensitivity profiles of Mycobacterium tuberculosis infection and associated factors in northeastern Ethiopia. BMC Infect Dis, 2021, 21(1):261. doi: 10.1186/s12879-021-05961-8.
doi: 10.1186/s12879-021-05961-8 pmid: 33711936 |
[34] |
Tiberi S, Cabibbe AM, Tomlins J, et al. Bedaquiline Phenotypic and Genotypic Susceptibility Testing, Work in Progress!EBioMedicine, 2018, 29:11-12. doi: 10.1016/j.ebiom.2018.02.006.
doi: 10.1016/j.ebiom.2018.02.006 |
[35] | World Health Organization. Technical Report on Critical Concentrations for Drug Susceptibility Testing of Medicines Used in the Treatment of Drug-Resistant Tuberculosis. Geneva: World Health Organization, 2018. |
[36] | The European Committee on Antimicrobial Susceptibility Testing. Breakpoint Tables for Interpretation of Mics and Zone Diameters.Switzerland: 2020. |
[37] |
Ismail N, Riviere E, Limberis J, et al. Genetic variants and their association with phenotypic resistance to bedaquiline in Mycobacterium tuberculosis: a systematic review and individual isolate data analysis. Lancet Microbe, 2021, 2(11):e604-e616. doi: 10.1016/s2666-5247(21)00175-0.
doi: 10.1016/s2666-5247(21)00175-0 |
[38] |
Degiacomi G, Sammartino JC, Sinigiani V, et al. In vitro Study of Bedaquiline Resistance in Mycobacterium tuberculosis Multi-Drug Resistant Clinical Isolates. Front Microbiol, 2020, 11:559469. doi: 10.3389/fmicb.2020.559469.
doi: 10.3389/fmicb.2020.559469 URL |
[39] |
Zhang S, Chen J, Cui P, et al. Identification of novel mutations associated with clofazimine resistance in Mycobacterium tuberculosis. J Antimicrob Chemother, 2015, 70(9):2507-2510. doi: 10.1093/jac/dkv150.
doi: 10.1093/jac/dkv150 pmid: 26045528 |
[40] |
Almeida D, Ioerger T, Tyagi S, et al. Mutations in pepQ Confer Low-Level Resistance to Bedaquiline and Clofazimine in Mycobacterium tuberculosis. Antimicrob Agents Chemother, 2016, 60(8):4590-4599. doi: 10.1128/AAC.00753-16.
doi: 10.1128/AAC.00753-16 pmid: 27185800 |
[41] |
Ismail NA, Omar SV, Moultrie H, et al. Assessment of epidemiological and genetic characteristics and clinical outcomes of resistance to bedaquiline in patients treated for rifampicin-resistant tuberculosis: a cross-sectional and longitudinal study. Lancet Infect Dis, 2022, 22(4):496-506. doi: 10.1016/S1473-3099(21)00470-9.
doi: 10.1016/S1473-3099(21)00470-9 URL |
[1] | 邓国防, 王庆文. 重视风湿性疾病合并结核感染的多学科诊治[J]. 中国防痨杂志, 2022, 44(9): 865-868. |
[2] | 国家感染性疾病临床医学研究中心/深圳市第三人民医院, 北京大学深圳医院, 中国医学科学院北京协和医院, 中国防痨协会, 《中国防痨杂志》编辑委员会, 深圳市炎症与免疫性疾病重点实验室. 风湿性疾病患者合并结核分枝杆菌潜伏感染诊治的专家共识[J]. 中国防痨杂志, 2022, 44(9): 869-879. |
[3] | 中华医学会结核病学分会超声专业委员会, 中国医师协会介入医师分会超声介入专业委员会单位. 结核性胸膜炎超声诊断、分型及介入治疗专家共识(2022年版)[J]. 中国防痨杂志, 2022, 44(9): 880-897. |
[4] | 包容, 高建峰, 饶艳. 实验性肺结核病变类型与特点[J]. 中国防痨杂志, 2022, 44(9): 898-905. |
[5] | 王玉香, 陈秋奇, 余鑫鑫, 詹森林, 张培泽, 邓国防. 3HP方案治疗风湿性疾病合并结核分枝杆菌潜伏感染的前瞻性研究[J]. 中国防痨杂志, 2022, 44(9): 906-910. |
[6] | 谢静仪, 邹瑞丰, 陈玉兰, 陈永, 刘冬舟, 洪小平. 系统性红斑狼疮合并结核感染临床特征及外周血淋巴细胞亚群分析[J]. 中国防痨杂志, 2022, 44(9): 911-916. |
[7] | 程晓, 陈哲, 焦雪峰, 杨楠, 刁莎, 倪晓凤, 刘峥, 何思颐, 曾力楠, 万朝敏, 康德英, 吴斌, 应斌武, 张慧, 赵荣生, 张伶俐. 重组结核杆菌融合蛋白(EC)用于诊断结核分枝杆菌感染的有效性和安全性系统评价[J]. 中国防痨杂志, 2022, 44(9): 917-926. |
[8] | 王倪, 黄飞, 竺丽梅, 曾谊, 张瑞梅, 耿红, 刘学法, 郑建刚, 宗佩兰, 曾忠, 李进岚, 蔡翠, 郭晓红, 钟引, 刘莉, 谢艳, 杜芳芳, 周林, 成诗明. 提高抗结核药品固定剂量复合剂在省市级结核病定点医院推广使用的实施性研究[J]. 中国防痨杂志, 2022, 44(9): 927-933. |
[9] | 魏赣辉, 张加成, 邱小伟. 容积CT值量化判断5mm以上肺结核病灶活动性的应用价值[J]. 中国防痨杂志, 2022, 44(9): 934-939. |
[10] | 王潮虹, 孙晴, 廖鑫磊, 晏君, 王晨倩, 姜广路, 王芬, 薛毅, 黄海荣, 王桂荣. 231例脊柱结核患者耐药情况分析[J]. 中国防痨杂志, 2022, 44(9): 940-946. |
[11] | 聂廷月, 陈伟, 张洁莹, 曹红, 钱冰, 顾颖强, 刘旭祥. 2009—2020年合肥市肺结核空间特征分析[J]. 中国防痨杂志, 2022, 44(9): 947-953. |
[12] | 吴文琪, 钟剑球, 何娟, 邓国防, 王庆文. 风湿性疾病患者结核分枝杆菌潜伏感染激活机制的研究进展[J]. 中国防痨杂志, 2022, 44(9): 954-959. |
[13] | 陈秋奇, 韩婷婷, 王庆文, 邓国防. 风湿性疾病合并结核分枝杆菌潜伏感染的诊治进展[J]. 中国防痨杂志, 2022, 44(9): 960-965. |
[14] | 韩旭, 关尚琪, 石银朋, 梅轶芳. 非肿瘤坏死因子靶向药物治疗类风湿关节炎的结核感染风险研究进展[J]. 中国防痨杂志, 2022, 44(9): 966-972. |
[15] | 谢芳晖, 梁丽, 赵霞, 姚蓉, 雷丽梅, 郭慧, 孟萌, 万彬. 肺结核患者痰标本采集的研究进展[J]. 中国防痨杂志, 2022, 44(9): 978-982. |
阅读次数 | ||||||
全文 |
|
|||||
摘要 |
|
|||||